Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 44

Sort by

Sort Order Select

Journal Articles

A phase 2 study of zanubrutinib in combination with rituximab and lenalidomide in de novo diffuse large B-cell lymphoma

Peng-Peng Xu, Yue Zhu, Zi-Yang Shi, Li Wang, Shu Cheng, Ying Qian, Yan Zhao, Yang He, Hong-Mei Yi, Bin-shen Ou-yang, Xu-Feng Jiang, Biao Li, Qi Song, Rong-Ji Mu, Wei-Li Zhao

Blood (2025) 146 (21): 2561–2573.

https://doi.org/10.1182/blood.2025028649

Published: 2025

Includes: Supplemental data

Journal Articles

Single-cell profiling of natural killer T-cell lymphoma reveals stratified immune features and therapeutic strategies

Qingqing Cai, Yi Cao, Danling Dai, Jinni Wang, Yuchen Zhang, Jie Xiong, Huiqiang Huang, Gao Yan, Yi Xia, Fang Liu, Xinna Gao, Shenrui Bai, Qihua Zou, Wei Li Zhao

Blood (2025) 146 (Supplement 1): 3527.

https://doi.org/10.1182/blood-2025-3527

Published: 2025

Journal Articles

Impact of TP53 mutation on CD19-chimeric antigen receptor T-cell therapy in large B-cell lymphoma

Ling-Shuang Sheng, Rong Shen, Zi-Xun Yan, Jinghua Zhao, Wen Wu, Wei Li Zhao, Li Wang

Blood (2025) 146 (Supplement 1): 1746.

https://doi.org/10.1182/blood-2025-1746

Published: 2025

Journal Articles

Rapid, efficient and durable fetal hemoglobin production following CS-101 treatment in transfusion-dependent β-thalassemia participants: An autologous, ex vivo edited CD34+ stem cell product using the innovative transformer base editor (tBE)

Jia Chen, Yongrong Lai, Xiaowen Zhai, Wei Li Zhao, Rongrong Liu, Xiaowen Qian, Wei Tang, Lijie Wang, Xu-Kai Ma, Yaliang Li, Jia Wei, Kewei Lan, Yan Zhang, Li Yang, Xiaodun (Susan) Mou

Blood (2025) 146 (Supplement 1): 6090.

https://doi.org/10.1182/blood-2025-6090

Published: 2025

Journal Articles

Clinical outcomes and safety of tislelizumab maintenance therapy following autologous stem cell transplantation in patients with relapsed or refractory diffuse large b-cell lymphoma

Meng-Meng Ji, Siyuan Chen, Yige Shen, Li Wang, Shu Cheng, Pengpeng Xu, Wei Tang, Wei Li Zhao

Blood (2025) 146 (Supplement 1): 3732.

https://doi.org/10.1182/blood-2025-3732

Published: 2025

Journal Articles

A phase II study of lenalidomide, zanubrutinib plus obinutuzumab in patients with FLIPI2 high-risk newly diagnosed follicular lymphoma: An interim analysis

Li Wang, Zhong Zheng, Ruichi Li, Pengpeng Xu, Shu Cheng, Wei Li Zhao

Blood (2025) 146 (Supplement 1): 7123.

https://doi.org/10.1182/blood-2025-7123

Published: 2025

Journal Articles

Tucidinostat plus R-CHOP in untreated MYC/BCL2 double-expressor diffuse large B-cell lymphoma：topline efficacy and safety results from the randomized phase 3 DEB study

Blood (2025) 146 (Supplement 1): 475.

https://doi.org/10.1182/blood-2025-475

Published: 2025

Journal Articles

Glofitamab in combination with CD19 CAR-T therapy for high-risk relapsed/refractory large B-cell lymphoma

Rong Shen, Ling-Shuang Sheng, Zi-Xun Yan, Yu-Yue Liang, Wen Wu, Li Wang, Wei Li Zhao

Blood (2025) 146 (Supplement 1): 3744.

https://doi.org/10.1182/blood-2025-3744

Published: 2025

Journal Articles

High HDAC I/IIb selective inhibitor purinostat mesylate in relapsed and refractory peripheral T-cell lymphoma: A single-agent phase IIa study

Ting Niu, Lin LIU, Huijing Wu, Keshu Zhou, Wei Yang, Li Wang, Shu Cheng, Jie Wang, Jinrong Yang, Fei Li, Shiyong Zhou, Yanhong Tong, Ke Tan, Adrian Rui Liang, linyu yang, Lijuan Chen, Wei Li Zhao

Blood (2025) 146 (Supplement 1): 5415.

https://doi.org/10.1182/blood-2025-5415

Published: 2025

Journal Articles

Efficacy and safety of zanubrutinib plus bendamustine-rituximab in newly diagnosed Mantle Cell Lymphoma with TP53 abnormalities or chemotherapy intolerance

Yaohui Huang, Siyi Chen, Shu Cheng, Pengpeng Xu, Wei Li Zhao, Li Wang

Blood (2025) 146 (Supplement 1): 5382.

https://doi.org/10.1182/blood-2025-5382

Published: 2025

Journal Articles

Zanubrutinib, rituximab, and high-dose methotrexate as first-line treatment in newly diagnosed primary central nervous system lymphoma （zana）: A prospective, single-arm study

Zhizhou Xia, Qifan Xu, Shu Cheng, Pengpeng Xu, Wei Li Zhao, Wang Li

Blood (2025) 146 (Supplement 1): 60.

https://doi.org/10.1182/blood-2025-60

Published: 2025

Journal Articles

Thyroid diffuse large B-cell lymphoma in China: Multicenter study of diagnosis, clinical features, treatment efficacy, prognostic factors, and genomic alterations

Blood (2025) 146 (Supplement 1): 1902.

https://doi.org/10.1182/blood-2025-1902

Published: 2025

Journal Articles

A prospective, multicenter, real-world study of glofitamab in Chinese patients with relapsed or refractory large B-cell lymphoma

Li Wang, Jiayin He, Zhihua Yao, Hongmei Jing, Songfu Jiang, Xia Zhao, Wenrong Huang, Hongbin Lu, Zhao Peiqi, Lihong Liu, Jianzhen Shen, Wei Li Zhao

Blood (2025) 146 (Supplement 1): 7252.

https://doi.org/10.1182/blood-2025-7252

Published: 2025

Journal Articles

Effectiveness and safety of axicabtagene ciloleucel (Axi-cel) in Chinese patients with relapsed/refractory non-Hodgkin lymphoma: Age subgroup analysis of real-world study

Zi-Xun Yan, Wenbin Qian, Ying Lu, Keshu Zhou, Dongmei Ji, Yuhua Li, Dehui Zou, Lanfang Li, Lei Zhang, Ping Li, Hongmei Jing, Chunyan Ji, Ting Niu, Fei Li, Xiaojian Zhu, Jinghua Zhao, Yu Hu, Depei Wu, Wei Li Zhao

Blood (2025) 146 (Supplement 1): 7230.

https://doi.org/10.1182/blood-2025-7230

Published: 2025

Journal Articles

Serum mirnas predict response to CAR-T cell therapy in large B-cell lymphoma

Ling-Shuang Sheng, Rong Shen, Zhong Zheng, Wen Wu, Li Wang, David Peng, Wei Li Zhao

Blood (2025) 146 (Supplement 1): 5307.

https://doi.org/10.1182/blood-2025-5307

Published: 2025

Journal Articles

Golidocitinib combined with CHOP in treatment-Naïve monomorphic epitheliotropic intestinal T-cell lymphoma: Preliminary results from A phase 2 multicenter, single-arm goal study

Yu-Ran Qiu, Ming-Ci Cai, Wenyu Li, Haiyan Yang, Jing Wang, Li Wang, Wei Li Zhao

Blood (2025) 146 (Supplement 1): 3649.

https://doi.org/10.1182/blood-2025-3649

Published: 2025

Journal Articles

A prospective, multicenter, randomized, controlled clinical trial comparing polatuzumab vedotin, zanubrutinib, lenalidomide, and rituximab (Pola-ZR2) versus zanubrutinib, lenalidomide, and rituximab (ZR2) in the treatment of previously untreated, elderly patients with diffuse large B-cell lymphoma (NCT06522555)

Fan Zhang, Zi-Yang Shi, Qing Shi, Yan Zhu, Wei Li Zhao, Li Wang

Blood (2025) 146 (Supplement 1): 3696.

https://doi.org/10.1182/blood-2025-3696

Published: 2025

Journal Articles

Practice pattern and outcomes in DLBCL by Genetic Subtypes: Preliminary results from a large-scale real-world study in China

Blood (2025) 146 (Supplement 1): 3689.

https://doi.org/10.1182/blood-2025-3689

Published: 2025

Journal Articles

Chidamide-BEAM conditioning plus autologous stem cell transplantation forperipheral t-cell lymphoma: A single-arm, single-center, phase 2 trial

Meng-Meng Ji, Yige Shen, Siyuan Chen, Wei Tang, Wei Li Zhao

Blood (2025) 146 (Supplement 1): 3631.

https://doi.org/10.1182/blood-2025-3631

Published: 2025

Journal Articles

CARMA-1: The phase I Study of SENL101, a naturally selected nanobody based CD7 CAR-T therapy, in relapsed or refractory T-ALL/lbl

Xiangyu Zhao, Wei Li Zhao, Xiaoxi Zhou, Huilai Zhang, Ting Niu, Hongsheng Zhou, Aibin Liang, Xi Zhang, Meng Lv, Lingshuang Sheng, Na Kuang, Xiaojun Huang

Blood (2025) 146 (Supplement 1): 5931.

https://doi.org/10.1182/blood-2025-5931

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

A phase 2 study of zanubrutinib in combination with rituximab and lenalidomide in de novo diffuse large B-cell lymphoma

Single-cell profiling of natural killer T-cell lymphoma reveals stratified immune features and therapeutic strategies

Impact of TP53 mutation on CD19-chimeric antigen receptor T-cell therapy in large B-cell lymphoma

Rapid, efficient and durable fetal hemoglobin production following CS-101 treatment in transfusion-dependent β-thalassemia participants: An autologous, ex vivo edited CD34+ stem cell product using the innovative transformer base editor (tBE)

Clinical outcomes and safety of tislelizumab maintenance therapy following autologous stem cell transplantation in patients with relapsed or refractory diffuse large b-cell lymphoma

A phase II study of lenalidomide, zanubrutinib plus obinutuzumab in patients with FLIPI2 high-risk newly diagnosed follicular lymphoma: An interim analysis

Tucidinostat plus R-CHOP in untreated MYC/BCL2 double-expressor diffuse large B-cell lymphoma：topline efficacy and safety results from the randomized phase 3 DEB study

Glofitamab in combination with CD19 CAR-T therapy for high-risk relapsed/refractory large B-cell lymphoma

High HDAC I/IIb selective inhibitor purinostat mesylate in relapsed and refractory peripheral T-cell lymphoma: A single-agent phase IIa study

Efficacy and safety of zanubrutinib plus bendamustine-rituximab in newly diagnosed Mantle Cell Lymphoma with TP53 abnormalities or chemotherapy intolerance

Zanubrutinib, rituximab, and high-dose methotrexate as first-line treatment in newly diagnosed primary central nervous system lymphoma （zana）: A prospective, single-arm study

Thyroid diffuse large B-cell lymphoma in China: Multicenter study of diagnosis, clinical features, treatment efficacy, prognostic factors, and genomic alterations

A prospective, multicenter, real-world study of glofitamab in Chinese patients with relapsed or refractory large B-cell lymphoma

Effectiveness and safety of axicabtagene ciloleucel (Axi-cel) in Chinese patients with relapsed/refractory non-Hodgkin lymphoma: Age subgroup analysis of real-world study

Serum mirnas predict response to CAR-T cell therapy in large B-cell lymphoma

Golidocitinib combined with CHOP in treatment-Naïve monomorphic epitheliotropic intestinal T-cell lymphoma: Preliminary results from A phase 2 multicenter, single-arm goal study

Practice pattern and outcomes in DLBCL by Genetic Subtypes: Preliminary results from a large-scale real-world study in China

Chidamide-BEAM conditioning plus autologous stem cell transplantation forperipheral t-cell lymphoma: A single-arm, single-center, phase 2 trial

CARMA-1: The phase I Study of SENL101, a naturally selected nanobody based CD7 CAR-T therapy, in relapsed or refractory T-ALL/lbl

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only